DiscussIntelia’s fourth quarter and full year 2019 operational highlights and financial results. This morning, we released a press release this quarter detailing our progress and the topics we plan to discuss in today’s call. This call is broadcast live, and the restart will be archived on our website. If you want to know more information, you can check at https://www.webull.com/quote/nasdaq-adi.
Before we begin, during this call, we may issue some forward-looking statements, and I urge you to refer to our SEC filings available on sec.gov for a discussion of potential risks and uncertainties. All information contained in this presentation is the same as it is today, and Intelia has no obligation to update this information unless required by law.
Joining me in today’s invitation to Intelia is our CEO, Dr. John Leonard; Dr. Laura Sepp-Lorenzino, our Chief Scientific Officer; And our Chief Financial Officer, Glenn Goddard. Following the feedback we made, we will be open to question and answer questions, for which our Chief Operating Officer, Andrew Schiermeier; Our Deputy General Counsel NishlaGeiser will also join.
Laura will provide an update on our R&D progress, and Glenn will review our financial results for the fourth quarter and the full year 2019. I will transfer the invitation to our CEO, John.
Here at Intellia, we are advancing our full spectrum gene editing strategy to create a diverse pipeline of in vivo and ex vivo projects to address life-threatening diseases. Our in vivo approach provides CRISPR / Cas9 components as therapy, and our former in vivo approach uses CRISPR / Cas9 as a tool to develop engineering cell-based therapeutics.
With strong progress through our pipeline, we hope that our modular approach and innovative science will position us well to transform genetic correction into new drugs. We have generated a strong prognostic data that support our ability to treat genetic diseases with single administration, and we are very pleased with the progress of our ex vivo approach, which we believe can capture the full promise of novel engineering cell therapy. Treatment for cancer and autoimmune diseases.
On the in vivo side, we believe that with our systemic lipid nanoparticle delivery system, we have opened up treatment for genetic diseases that originate in the liver. We have proven, we can select genes that carry diseases and can accurately insert chains to produce normal human proteins for therapeutic purposes. In the former in vivo page, we focus on engineered lymphocytes that retain normal cell physiology targeting various fluid and solid tissue cancers. If you want to know more stock news, you can check at https://www.webull.com/quote/nyse-w.